Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction - Wikidata - awgldk - TriplyDB

Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction

Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction

http://www.wikidata.org/entity/Q34313113

about

X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy Reactive oxygen species in inflammation and tissue injury Spatial regulation of VEGF receptor endocytosis in angiogenesis Diabetic macular edema: new concepts in patho-physiology and treatment.Vascular endothelial growth factor-A165b ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina.Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors PKCζ mediates breakdown of outer blood-retinal barriers in diabetic retinopathy Beta-adrenergic receptor agonist decreases VEGF levels through altered eNOS and PKC signaling in diabetic retina.Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathy Ezrin/radixin/moesin proteins differentially regulate endothelial hyperpermeability after thrombin.Role of endothelium in vasomotor responses to endothelin system and protein kinase C activation in porcine retinal arterioles Compound 49b Regulates ZO-1 and Occludin Levels in Human Retinal Endothelial Cells and in Mouse Retinal Vasculature.Regulatory mechanisms, prophylaxis and treatment of vascular leakage following severe trauma and shock.Neuropeptides and diabetic retinopathy.Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications.Gold Nanoparticles Increase Endothelial Paracellular Permeability by Altering Components of Endothelial Tight Junctions, and Increase Blood-Brain Barrier Permeability in Mice.Diabetic retinopathy: Breaking the barrier.IGFBP-3 reduces eNOS and PKCzeta phosphorylation, leading to lowered VEGF levels.Occludin S471 Phosphorylation Contributes to Epithelial Monolayer Maturation.The EPAC-Rap1 pathway prevents and reverses cytokine-induced retinal vascular permeability.

P2860

Q26777270-CD2EAE66-0C17-4A42-9C30-C343D0667593 Q27021701-CB939AA6-76A9-494D-85E0-025D3D04AB61 Q28396273-A6265ED1-99CD-4E9C-B63E-62099727CA28 Q28585752-9ECE3AAA-1F1B-4E13-9E06-6DC6E4376454 Q33713517-D6E2DF5E-0F3D-401A-BE28-3B06DE2AD62E Q33742338-6CE780DF-CD85-4486-A76C-628D1B8694B2 Q34553087-6C479F2B-E4DD-4488-A426-CF18DC3A6599 Q34659495-5CDA9F3B-C8FE-48E7-AAC2-71632E1619A2 Q35060608-2965AB38-5C84-4CB2-A10C-4273DEF51202 Q36687280-8108B6D1-6F83-44A4-9219-72DC288FF782 Q36867626-5FFA24EB-6907-43FE-A094-ECDE4FA02B51 Q37094211-37B24815-3F3E-4F35-BA75-7362B45E636F Q37328871-A905E32E-9B6F-45EB-90A3-34C9A1CB37D4 Q37600478-C415234A-30C6-4040-B2F3-1D269F3C42DC Q37726288-04287654-E1DF-483D-85AC-6EE45FA5BF57 Q38050159-2166C074-1EBD-4403-B3E9-D057C1795C8A Q38112711-39C39D03-2B1E-48D3-889D-0FDE0CF2311A Q38843804-1A3665CA-CEBB-4817-90B7-4C5A1B91F477 Q39451009-516AE1CF-79DA-401E-95AB-E05F920A76B3 Q41066130-210FC6E5-CFA9-4EAB-91B0-F090B12AD0D4 Q42418341-F8DA530F-C786-485F-A1D0-0043F3D44FE7 Q47381646-7F52F5F9-7873-4DD1-A151-D05CC9CC1A5C

P2860

Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction

http://www.wikidata.org/entity/Q34313113

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@ast

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@en

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@nl

type

label

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@ast

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@en

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@nl

prefLabel

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@ast

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@en

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@nl

P1433

Q34313113-EFF5A439-407E-4FC4-B446-A713B04787CD

P1476

Q34313113-FFA0F16F-8252-4433-AC4D-7E7B54B858E5

P2093

Q34313113-11CCBB59-3BC9-4BDC-AAD3-2162DDFB5FCF

Q34313113-3F1BB670-AC97-418C-86D0-16F75EFA50A8

Q34313113-8240F850-A3EF-4082-ADF2-87B34E52D64B

Q34313113-A6DC8815-6FFD-44B7-9670-E471111917D0

Q34313113-BFF07A30-74F2-4AD0-8F9F-E57AB4D9FB68

Q34313113-E1747CC2-DD2B-41C5-AC66-E4626519FFAD

P2860

Q34313113-071BE1CE-69DA-4967-9B1E-A4F44E0A7182

Q34313113-136ADB6F-A8A8-4704-ACFF-C771799579A3

Q34313113-14551F7D-89A0-400E-B66D-B79B4AF7EC32

Q34313113-14D8B2A2-91FF-48AC-BF2D-AB6452641E49

Q34313113-198A28D9-D652-40ED-A108-70BE18FF82DE

Q34313113-1A1B1B08-999D-4669-87A5-E56148875C64

Q34313113-1E369B80-6297-4C6E-9A10-1EDBFDF4C3AC

Q34313113-20B868E1-418E-467A-9FAC-2FBD3902005B

Q34313113-21E66093-4301-4C51-ACA5-06B5ED39377E

Q34313113-23E4654C-D21E-4350-A27E-83EC02478B45

P304

Q34313113-4ADC70E5-5739-4109-BBAC-374764FE712E

P31

Q34313113-233C5928-F33F-435D-AF15-F970757C3B45

P356

Q34313113-8DD87A78-DD65-4EA7-AA3A-A78A5F6E9F9D

P407

Q34313113-BDED273A-56F3-40DF-A4AC-0C23496427D3

P433

Q34313113-C852EA3D-0AA6-45B2-A0E2-C83703E366D7

P478

Q34313113-B085B3A8-3290-439B-8927-693B151A08D1

P577

Q34313113-AD07230A-BFFE-442F-9D87-F9CD266C2E3E

P5875

Q34313113-F68D8A6F-A516-4767-8D2D-1F81D633CC4A

P698

Q34313113-67EBD456-5A49-46C4-82E0-1FD1D8C97BAE

P921

Q34313113-F804C64B-694B-4E9A-8007-F74A4C1156BD

P932

Q34313113-AA2164BA-58A7-4015-A012-BD10472B6BF4

P356

P1433

Biochemical Journal

P1476

Novel atypical PKC inhibitors ...... od-retinal barrier dysfunction

@en

P2093

Charles D Smith

http://www.w3.org/2001/XMLSchema#string

Cheng-Mao Lin

http://www.w3.org/2001/XMLSchema#string

David A Antonetti

http://www.w3.org/2001/XMLSchema#string

Jason M Keil

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Sundstrom

http://www.w3.org/2001/XMLSchema#string

Paul M Titchenell

http://www.w3.org/2001/XMLSchema#string

P2860

2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor

Identification and Analysis of Occludin Phosphosites: A Combined Mass Spectrometry and Bioinformatics Approach

Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression

Nucleolin is a protein kinase C-zeta substrate. Connection between cell surface signaling and nucleus in PC12 cells

Regulation of protein kinase C zeta by PI 3-kinase and PDK-1

Parsing the polarity code.

Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.

Sensitive blood-retinal barrier breakdown quantitation using Evans blue.

Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter.

Etiology and treatment of macular edema.

P304

455-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BJ20111961

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

446

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227856255

http://www.w3.org/2001/XMLSchema#string

P698

22721706

http://www.w3.org/2001/XMLSchema#string

P921

P932

3767384

http://www.w3.org/2001/XMLSchema#string